Management
Paul Averback, MD, DABP, President and CEO
Dr. Paul Averback is the founder, CEO and President of Nymox. He is the inventor of Nymox's spheron-based technologies and co-inventor with other scientists of many of Nymox's other proprietary technologies. Dr. Averback has a vast experience as a successful independent entrepreneur, scientific researcher, medical specialist and front-line medical practitioner. He has successfully negotiated several strategic research collaborations with large multinational pharmaceutical companies in the US, Europe, and Japan. Dr. Averback has extensive firsthand knowledge of health care, including as an emergency room physician, family physician, clinic administrator and university Medical Faculty member. In addition to many issued and pending patents, Dr. Averback has published prolifically in the scientific and medical literature on subjects such as Alzheimer's disease, pharmaceuticals, neuropathology, neuroanatomy, diagnostics, vascular disease, oncology, cytology, congenital disease, embryology, geometrical probability and morphometry. Dr. Averback (MD '75) holds a Diploma of the American Board of Pathology with Special Competence in Neuropathology, was a Medical Research Council Postdoctoral Fellow at Cambridge University, England (1977-1980), and was on the Faculty of Medicine at McGill University (1980-1985).
Roy M. Wolvin, B.A.(Econ.), Secretary-Treasurer and Chief
Financial Officer
Roy Wolvin has been Secretary-Treasurer and Chief Financial Officer
since September 1995. Previously, he held managerial positions at the CIBC and the Royal Bank. Mr. Wolvin holds
a degree in Economics from the University of Western Ontario.
Jack Gemmell, B.Sc.(Hons.), LL.B., General Counsel and Chief Information Officer
Jack Gemmell graduated from the Faculty of Law at the University of Toronto in 1977 and was called to the bar in 1979. He practiced primarily in the area of litigation for over 19 years before joining Nymox in July, 1998 and has substantial business experience.
